Welcome to BCIQ: BioCentury Online Intelligence.
Free access to this and other abridged company profiles is provided to all subscribers to SciBX: Science-Business eXchange.

Please explore the profile and if you wish to find out more about BCIQ - please Click Here

Active Biotech AB

Print preview

(SSE:ACTI)

General Information

Location	Lund, Sweden
Region
Country	Sweden
Business Category	Cancer, Autoimmune
Year Founded	1996
Website	www.activebiotech.com
Development Status	Phase III (11/09/2007)

Archive Items are loading

Financial Information

Financing Summary

Total Money Raised	Number of Completed Financings	Last Financing Date	Last Financing Type	Number of All Financings
$184,848,599	7	06/15/2009	Rights offering (other)	7

Financing Details (7 records)

Company Name	Financing Status	Date Completed	Financing Type	Amount Raised	Share Price	Post-Money Valuation
Active Biotech AB	Completed	06/15/2009	Rights offering (other)	$32,743,503	SEK20	$161,155,431
Active Biotech AB	Completed	06/12/2008	Rights offering (other)	$26,708,797	SEK40.00	$347,214,376

Financial Performance Summary

	1Q08	2Q08	3Q08	4Q08	1Q09
As Of Date	03/31/2008	06/30/2008	09/30/2008	12/31/2008	03/31/2009
Profit and loss
Sales	$539,200	$431,860	$441,000	$5,757,860	$265,760
Revenues	$0	$0	$0	$0	$0
SG&A	$960,450	$1,079,650	$1,749,300	$839,150	$531,520
R&D	$8,391,300	$8,072,460	$7,835,100	$7,190,870	$7,429,200
Operating Income	($8,795,700)	($8,720,250)	($9,158,100)	($2,272,160)	($7,694,960)
Net Income	($8,997,900)	($7,640,600)	($9,216,900)	($2,530,360)	($7,513,760)
EPS	-$0.19	-$0.16	-$0.18	-$0.05	-$0.15
Diluted EPS
Shares Outstanding	47,300,000	48,600,000	51,242,000	51,242,000	51,242,000
Balance Sheet
Cash	$15,535,700	$35,545,400	$23,608,200	$17,906,170	$8,673,440
Valuations
Market Cap	$453,753,630	$339,968,000	$317,874,623	$204,281,357	$245,551,664
Tech Value	$438,217,930	$304,422,600	$294,266,423	$186,375,187	$236,878,224
R&D/Sales
R&D/Revenue
SG&A/Sales	1.78	2.50	3.97	0.15	2.00
SG&A/Revenue
Currency Rate
Rate	0.1685	0.1661	0.1470	0.1291	0.1208

Stocks Annual Chart

Pipeline Information

Pipeline Summary

Disease Category	Research	Phase I	Phase I/II	Phase II	Phase II/III	Phase III	Registration	Approved	Marketed
Autoimmune	-	2	1	-	-	1	-	-	-
Cancer	-	2	-	1	-	1	-	-	-
Total	-	4	1	1	-	2	-	-	-

Pipeline Details - Originated and out-licensed products (7 records)

Product Names	Disease Category	Standard Indication	Partners	Milestones	Latest Stage of Development
5062 (Compound #), laquinimod (Generic), SAIK-MS (Informal)	Autoimmune	Crohn's disease	Teva Pharmaceutical Industries Ltd.		Phase I
5062 (Compound #), laquinimod (Generic), SAIK-MS (Informal)	Autoimmune	Multiple sclerosis (MS)	Teva Pharmaceutical Industries Ltd.		Phase III

Pipeline Details - In-licensed products

Product Names	Disease Category	Standard Indication	In-licensed from	Milestones	Latest Stage of Development	Rights
RhuDex (Other)	Autoimmune	Rheumatoid arthritis (RA)	MediGene AG		Phase I/II	Development

ACCESS TO BIOCENTURY ONLINE INTELLIGENCE (BCIQ) AND THE BIOCENTURY ARCHIVES IS LIMITED ONLY TO AUTHORIZED SUBSCRIBERS WHO HAVE READ AND AGREED TO THE BIOCENTURY USER AGREEMENT, WHICH SOLELY GOVERNS THE CONDITIONS FOR USE OF ANY OF THESE SERVICES AND THE INFORMATION CONTAINED THEREIN. All contents Copyright © 1994-2009 BioCentury Publications, Inc. ALL RIGHTS RESERVED. These Services and the Content contained therein are protected under U.S. and foreign copyright and intellectual property laws, and may not be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness®; Because Real Intelligence is Hard to Find™; BCIQ™; The BioCentury 100™; and The Clear Route to ROI™ are trademarks of BioCentury Publications, Inc., P.O. Box 1246 San Carlos, CA 94070.